Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | DPYD | Q12882 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | THPO | P40225 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HBB | P68871 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31045646 | 0.83 | CYP3A4 (0.56) | CYP3A4MAPTMEN1KMT2AKDM4E | |
| SCHEMBL21184262 | 0.76 | MAPT (0.54) | CYP3A4MAPTMEN1KMT2AKDM4E | |
| SCHEMBL30608338 | 0.73 | MAPT (0.59) | CYP3A4MAPTMEN1KMT2AKDM4E | |
| SCHEMBL1518339 | 0.71 | MAPT (0.50) | CYP3A4MAPTMEN1KMT2AKDM4E | |
| SCHEMBL4961428 | 0.71 | LMNA (0.54) | CYP3A4MAPTMEN1KMT2AKDM4E | |
| SCHEMBL23133109 | 0.70 | KDM4E (0.56) | MAPTMEN1KMT2AKDM4ETAAR1 | |
| SCHEMBL2552963 | 0.70 | CYP3A4 (0.57) | CYP3A4MAPTMEN1KMT2AKDM4E | |
| SCHEMBL30464745 | 0.69 | CYP3A4 (0.49) | CYP3A4DPYD | |
| SCHEMBL30464746 | 0.69 | CYP3A4 (0.49) | CYP3A4DPYD | |
| SCHEMBL17803639 | 0.69 | CA12 (0.37) | CYP3A4KMT2AKDM4ELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1005 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122029176-A | Containing a plurality of oligonucleotides modified oligonucleotides | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-122028913-A | Oligonucleotides containing ligands in nucleobases, 2 'or 3' positions | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-122029177-A | Oligonucleotides containing multiple ligands and/or lipids | 阿达尔克斯制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-119095964-A | Multi-tail and multi-cap mRNA and uses thereof | 博德研究所 | 2024-12-06 | — | — | CN | claimed |
| CN-118076741-A | Modified mRNA, modified non-coding RNA and uses thereof | 布罗德研究所股份有限公司 | 2024-05-24 | — | — | CN | claimed |
| WO-2013071079-A1 | LIN28/LET-7 CRYSTAL STRUCTURES, PURIFICATION PROTOCOLS, AND MOLECULAR PROBES SUITABLE FOR SCREENING ASSAYS AND THERAPEUTICS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-05-16 | — | — | WO | claimed |
| CN-122095092-A | Inhibitor for inhibiting inhibin Beta E gene expression and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122095091-A | DsRNA for inhibiting LPA gene expression and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260138999-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | BRISTOL MYERS SQUIBB CO (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026106956-A1 | DISULFIDE-STABILIZED NOROVIRUS VIRUS-LIKE PARTICLE DESIGN | MERCK SHARP & DOHME LLC (US) | 2026-05-21 | — | — | WO | disclosed |
| US-12629412-B2 | Betacoronavirus mRNA vaccines | MODERNATX, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| WO-2026098737-A1 | NUCLEIC ACID CONJUGATE AND PHARMACEUTICAL COMPOSITION FOR LIPID DELIVERY, AND USE THEREOF | 苏州时安生物技术有限公司 | 2026-05-15 | — | — | WO | disclosed |
| CN-122038302-A | Modified T cells and methods of making and using the same | 哈佛学院校长同事会 | 2026-05-15 | — | — | CN | disclosed |
| WO-2010011895-A1 | ENHANCEMENT OF SIRNA SILENCING ACTIVITY USING UNIVERSAL BASES OR MISMATCHES IN THE SENSE STRAND | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2009155504-A2 | METHODS FOR THE MODULATION OF ANGIOGENESIS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009149239-A1 | METHODS OF MODULATING ANGIOGENESIS VIA TRPV4 | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009126933-A2 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009120878-A2 | NON-NATURAL RIBONUCLEOTIDES, AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| WO-1995006751-A9 | METHODS FOR ISOLATION OF MOST ABUNDANT OLIGONUCLEOTIDES FROM COMPLEX MIXTURES | — | 1995-04-20 | — | — | WO | disclosed |
| WO-1995006751-A1 | METHODS FOR ISOLATION OF MOST ABUNDANT OLIGONUCLEOTIDES FROM COMPLEX MIXTURES | PHARMAGENICS, INC. (US) | 1995-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138999-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | RNGTT, CDA, DCTD | CYP3A4 3396/4885MAPT 4097/4885MEN1 4354/4885 |
| US-12629412-B2 | Betacoronavirus mRNA vaccines | RNMT, RNGTT, METTL16 | CYP3A4 3105/4885MAPT 1032/4885MEN1 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.